ArticleJournal of neurology, neurosurgery, and psychiatry2023
Association of obesity with disease outcome in multiple sclerosis.
Article in Journal of neurology, neurosurgery, and psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07207148 (People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists), which is not on this map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Uncovering the Causal Link Between Obesity-Associated Genes and Multiple Sclerosis: A Systematic Literature Review.Brain and behavior · 2025Pooled it
- Effects of vascular disease risk factors on brain metabolism in multiple sclerosis.Multiple sclerosis and related disorders · 2025Trial
- Randomised controlled trial of intermittent calorie restriction in people with multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2025Trial
- Sustained Benefits of a Multidomain Lifestyle Intervention in Multiple Sclerosis in the LIMS Study: A 24-Month Follow-Up.Neurology · 2026Observational
- Glucagon-Like Peptide-1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review.Annals of clinical and translational neurology · 2026Review
- Genetic modification of obesity-associated disability progression in multiple sclerosis.Journal of neurology · 2026Article
- Mediation Analysis Between Brain Age, Disease-Modifying Factors, and Disability and Cognitive Performance in Multiple Sclerosis.Neurology · 2026Article
- Body Composition Analysis in Young Patients with Recent Diagnosis of Multiple Sclerosis: An Exploratory Study.Journal of clinical medicine · 2026Article
- Preventive strategies in neuroimmunology.Neurological research and practice · 2026Review
- IL-27-964 A/G polymorphism promoter polymorphism, serum IL-27, and vitamin D in multiple sclerosis: evidence from an egyptian case-control study.Molecular biology reports · 2026Article
- The obesity-brain axis: a comprehensive review of neurological complications and therapeutic interventions in metabolic syndrome.Diabetology & metabolic syndrome · 2026Review
- Long-term impact of newly-proposed clinical obesity on autoimmune disease incidence: insights from the UK Biobank.International journal of obesity (2005) · 2026Article
- The association between BMI and cognition, disability, and quality of life markers in multiple sclerosis: DISCOMS secondary analysis.Therapeutic advances in neurological disorders · 2026Article
- Investigating the treatment of vascular risk with simvastatin in secondary progressive multiple sclerosis: analysis from the MS-STAT2 randomized controlled trial.Brain communications · 2026Article
- Impact of tobacco and alcohol consumption on disease progression and MRI in people with multiple sclerosis: results of the prospective cohort study NationMS.Therapeutic advances in neurological disorders · 2026Article
- From Limited Samples to Mechanistic Insights: Exploratory Identification and Functional Validation of a hsa_circ_0062400/hsa_circ_0002397-miR-338-3p-NRP1 Axis in Myasthenia GravisEndocrine, metabolic & immune disorders drug targets · 2026Article
- Comorbidity and modifiable risk factors in multiple sclerosis.Therapeutic advances in neurological disorders · 2026Review
- Persons With Multiple Sclerosis Reveal Distinct Kynurenine Pathway Metabolite Patterns: A Multinational Cross-Sectional Study.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Early-life and adult body mass index in relation to MS disability progression.Journal of neurology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 17 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity reportedly increases the risk for developing multiple sclerosis (MS), but little is known about its association with disability accumulation.
methodsThis nationwide longitudinal cohort study included 1066 individuals with newly diagnosed MS from the German National MS cohort. Expanded Disability Status Scale (EDSS) scores, relapse rates, MRI findings and choice of immunotherapy were compared at baseline and at years 2, 4 and 6 between obese (body mass index, BMI ≥30 kg/m
resultsPresence of obesity at disease onset was associated with higher disability at baseline and at 2, 4 and 6 years of follow-up (p<0.001). Median time to reach EDSS 3 was 0.99 years for patients with BMI ≥30 kg/m
conclusionsObesity in newly diagnosed patients with MS is associated with higher disease severity and poorer outcome. Obesity management could improve clinical outcome of MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.